A recent study suggests that people who stop using new GLP-1 drugs like semaglutide or tirzepatide can put back on shed pounds at a significantly accelerated pace than those who end conventional diet and exercise regimens.
Published data in a leading health publication demonstrates that while overweight people often shed a large proportion of their body weight while undergoing treatment, the mass is regained at an average rate of nearly a kilo each month once they quit.
"Users buying such medications must be cognizant of the risk of quick rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a reversion to starting mass in about a year and a half.
Analyzing Treatments
The research, which reviewed 37 of studies involving thousands of patients, compared the results of GLP-1 agonists with conventional dieting.
Researchers emphasize that individuals who lose weight through lifestyle changes alone usually see a slower weight regain—perhaps 0.1 kg a month—after stopping.
Explaining the Rapid Regain
Experts believe the way of the jabs is key to understanding the amplified rebound.
These medications mimic a body's own chemical called GLP-1, which controls appetite.
"Artificially providing GLP-1 concentrations several times higher than the body's typical production could lead to the system to produce less of its own natural hormone, and could lessen sensitivity to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this GLP-1 'fix' results in appetite is unsuppressed, making excessive eating much more probable."
An Ongoing Condition?
Medical guidelines recommend the injections for individuals with obesity-related health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, given the likelihood of relapse, the therapy should be considered ongoing.
This opinion is supported by drug manufacturers, who state that the results "highlight the persistent nature of excess weight," akin to managing conditions like hypertension.
Patient Testimonies
Individuals who have discontinued the jabs report a intense return of appetite.
"It was like something that goes on and I was suddenly starving," said an individual.
This challenge is worsened if individuals have not established sustainable dietary or behavioural changes during treatment.
Widespread Use
Recent estimates indicate that a significant number of people in the UK have used these injections in the last 12 months, with demand being substantial.
- Use is more common among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, experts emphasize that while these medications are potent tools for weight loss, they are not a permanent fix and lasting health benefits relies on combined behavioural support.
